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Percutaneous closure of a ventricular septal defect after surgical
treatment of hypertrophic cardiomyopathy
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Surgery or ethanol ablation is indicated in patients withhypertrophic cardiomyopathy who have symptomaticNew York Heart Association (NYHA) class III diseasewith severe left ventricular outflow tract (LVOT) gradi-
ents despite medical treatment.1 A ventricular septal defect (VSD)
after surgical treatment is rare.2 Alternatives for surgical closure
are available in patients with congenital VSDs or post–myocardial
infarction VSDs. Percutaneous closure provides a reasonable al-
ternative.3,4
We describe the technique of percutaneous closure of a VSD
after surgery for hypertrophic cardiomyopathy.5
Clinical Summary
A 50-year-old man was referred for surgery with symptomatic
hypertrophic cardiomyopathy despite medical therapy. He was in
NYHA class III with effort-related angina. Echocardiography
showed asymmetrical left ventricular hypertrophy with a septal
end-diastolic thickness of 19 mm, systolic anterior motion, an
ejection fraction of 66%, and an LVOT gradient of 64 mm Hg.
During catheterization the pressure gradient measured 100 mm Hg.
Ethanol ablation failed. A surgical procedure was performed via a
transaortic approach. By a Morrow septal myomectomy the LVOT
was increased from 16 to 23 mm. However, on control transesoph-
ageal echocardiography the distal part of the LVOT was still
obstructive. This part being out of reach, a second attempt was
made via the left atrium during the same procedure. The antero-
external commissure and the A1 and A2 portions of the anterior
leaflet of the mitral valve were detached from the annulus, and the
myomectomy was completed distally. The anterior leaflet of the
mitral valve was reattached to the annulus. Control echocardiog-
raphy showed total relief of the LVOT obstruction, absence of
mitral regurgitation, but a small muscular VSD. The initial post-
operative course was uneventful. During the following weeks, the
patient’s clinical condition deteriorated, with left and right ven-
tricular failure and mild renal and hepatic failure. On control
echocardiography a muscular VSD 12 mm in diameter with a
left-to-right shunt of 2:1 and half systemic right ventricular pres-
sure was seen. At the right side of the ventricular septum, the VSD
was located near the attachments of the septal leaflet of the
tricuspid valve; at the left side, the distance from the aortic valve
was 18 mm. The thickness of the septum surrounding the VSD
varied between 10 and 14 mm.
On the 20th postoperative day, percutaneous closure of the
VSD was attempted. Under fluoroscopy and transesophageal echo-
cardiographic guidance, the VSD could be crossed via the right
jugular vein and a Mullins transseptal sheath was positioned in the
left ventricle. An Amplatzer 14-mm VSD occluder (AGA Medical
Corporation, Golden Valley, Minn) was delivered in the VSD and
released (Figure 1). The patient had a second-degree atrioventric-
ular block necessitating temporary pacing. Hemodynamic recovery
was immediate, but the postoperative course was complicated by
transient hemolysis and Candida septicemia. One month after
closure of the VSD, the patient could be dismissed. An echocar-
diogram showed a correct position of the VSD device, without any
gradient or residual shunt across the LVOT (Figure 2).
Discussion
A VSD complicating surgery for LVOT obstruction in hypertro-
phic cardiomyopathy is rare.2 These VSDs can be hemodynami-
cally significant. Surgical closure of a VSD can be cumbersome in
a patient who has had recent surgery. Percutaneous or perventricu-
From the Departments of Congenital Cardiology,a Cardiology,b and Cardiac
Surgery,d Ghent University Hospital, Ghent, Belgium, and the Department of
Congenital Cardiology,c Antwerp University Hospital, Antwerp, Belgium.
Received for publication Dec 23, 2005; revisions received Jan 4, 2006;
accepted for publication Jan 10, 2006.
Address for reprints: Daniël De Wolf, MD, PhD, Kindercardiologie UZ Gent,
De Pintelaan 185, 9000 Gent, Belgium (E-mail: Daniel.dewolf@ugent.be).
J Thorac Cardiovasc Surg 2006;132:173-4
0022-5223/$32.00
Copyright © 2006 by The American Association for Thoracic Surgery
doi:10.1016/j.jtcvs.2006.01.051
Brief Communications
The Journal of Thoracic and Cardiovascular Surgery ● Volume 132, Number 1 173
lar closure of muscular VSDs has been reported,3,4 with reasonable
results and limited complications. Percutaneous closure has been
advocated for the closure of postinfarction VSDs in adults also, but
with lower success rates.4 Only a few reports address percutaneous
closure of a VSD after surgery for hypertrophic cardiomyopathy.5
In this case, the percutaneous technique to close the VSD
proved successful, but several complications have been encoun-
tered. Unlike this case, the procedure can be technically challeng-
ing and lead to rhythm disturbances or damage to the tricuspid
valve.
Moreover, conduction tissue can run near the edges of the VSD
and be damaged by manipulation of the device. The risk is more
important if the VSD is located near the aortic or tricuspid valves
and can result in temporary or permanent atrioventricular block.3,4
Hemolysis caused by residual flow through the fabric of the
device is widely known and generally self-limiting.3,4
The devices do not always present with a nice flat profile after
release. We hesitated before implanting such a device in a narrow
LVOT, fearing obstruction. This did not occur.
Most devices become completely endothelialized within 6
months after implantation. In the meanwhile, the device is foreign
material in the circulation and can become infected. Any infection
during this period should be aggressively treated with careful
echocardiographic inspection for possible vegetations.
Conclusion
A VSD is rare after surgery or ethanol septal ablation for severe
LVOT obstruction in hypertrophic cardiomyopathy. Percutaneous
closure offers a reasonable therapeutic option in symptomatic
patients.
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Figure 1. Fluoroscopic image before release of the VSD device.
The device is seen on the image to the right of the transesoph-
ageal echocardiography probe in front of the vertebral column. It
is fully deployed in the VSD but still attached to the delivery wire
(arrow) in the sheath.
Figure 2. Echocardiographic image of the device during follow-up
(long axis). The left part of the device is seen as a dense crescent-
like structure at the left side of the interventricular septum. The LVOT
is unobstructed. LV, Left ventricle; LA, left atrium.
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